OncoCyte (NASDAQ:OCX) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX) in a research note issued on Friday. The brokerage set a “sell” rating on the stock.

Several other equities research analysts have also recently weighed in on OCX. Benchmark lowered their price objective on shares of OncoCyte from $9.00 to $5.00 and set a “speculative buy” rating for the company in a research report on Thursday, August 24th. Needham & Company LLC lowered their price target on shares of OncoCyte from $9.00 to $4.25 and set a “buy” rating for the company in a research report on Thursday, August 10th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. According to MarketBeat.com, OncoCyte presently has an average rating of “Hold” and an average target price of $7.31.

OncoCyte Trading Down 0.6 %

OncoCyte stock opened at $3.28 on Friday. The firm’s 50 day moving average price is $3.63 and its two-hundred day moving average price is $4.09. OncoCyte has a twelve month low of $3.24 and a twelve month high of $18.60.

OncoCyte (NASDAQ:OCX) last announced its quarterly earnings results on Thursday, August 10th. The company reported ($1.07) EPS for the quarter, topping the consensus estimate of ($2.60) by $1.53. The business had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.60 million. As a group, sell-side analysts expect that OncoCyte will post -3.03 earnings per share for the current fiscal year.

Institutional Investors Weigh In On OncoCyte

A number of large investors have recently bought and sold shares of OCX. Raymond James Financial Services Advisors Inc. acquired a new stake in OncoCyte during the 1st quarter worth approximately $25,000. Vanguard Group Inc. raised its holdings in OncoCyte by 2.3% during the 1st quarter. Vanguard Group Inc. now owns 3,986,270 shares of the company’s stock worth $5,940,000 after purchasing an additional 90,534 shares during the last quarter. DCF Advisers LLC raised its holdings in OncoCyte by 107.0% during the 1st quarter. DCF Advisers LLC now owns 25,149 shares of the company’s stock worth $37,000 after purchasing an additional 13,000 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of OncoCyte by 5.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 460,004 shares of the company’s stock valued at $686,000 after acquiring an additional 24,964 shares in the last quarter. Finally, LPL Financial LLC increased its stake in shares of OncoCyte by 58.1% in the 2nd quarter. LPL Financial LLC now owns 108,816 shares of the company’s stock valued at $98,000 after acquiring an additional 40,000 shares in the last quarter.

About OncoCyte

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.